Last Round
Series A
Extension
Jul 26, 2023
Total Funding Raised
$61.2M
Company Overview
AsclepiX Therapeutics is a biopharmaceutical company that develops novel peptide therapeutics for the treatment of retinal diseases and cancer using computational biology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AsclepiX Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
AsclepiX Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jul 26, 2023 | ||||
| Series A | Jun 24, 2020 | ||||
| Convertible Debt | Nov 13, 2018 | ||||
| Grant | Nov 12, 2018 | ||||
| Convertible Debt | Jul 22, 2016 |
AsclepiX Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hibiscus BioVentures | Series A Extension |
| National Cancer Institute | Grant |
| National Eye Institute (NIH) | Grant |
| Barer & Son Capital | Series A, Convertible Debt |
| Perceptive Advisors | Series A, Series A Extension |
| Research to Prevent Blindness | Grant |
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2023
$10M round led by Perceptive Advisors.
- Nov 12, 2018
$11M grant round from TEDCO and NIH institutes.
AsclepiX Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AsclepiX Therapeutics's valuation, stock price, and market status.